M
Mark C. Genovese
Researcher at Stanford University
Publications - 374
Citations - 29955
Mark C. Genovese is an academic researcher from Stanford University. The author has contributed to research in topics: Rheumatoid arthritis & Placebo. The author has an hindex of 79, co-authored 364 publications receiving 26945 citations. Previous affiliations of Mark C. Genovese include New York State Department of State & Incyte.
Papers
More filters
Journal ArticleDOI
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mark C. Genovese,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Barbara K. Finck +11 more
TL;DR: Subcutaneous [corrected] etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.
Journal ArticleDOI
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward C. Keystone,J.E. Loveless,Gerd-Rüdiger Burmester,M. Cravets,E. W. Hessey,T. Shaw,Mark C. Totoritis +12 more
TL;DR: At 24 weeks, a single course of rituximab with concomitant MTX therapy provided significant and clinically meaningful improvements in disease activity in patients with active, longstanding RA who had an inadequate response to 1 or more anti-TNF therapies.
Journal ArticleDOI
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Mark C. Genovese,Jean-Claude Becker,Michael Schiff,Michael E. Luggen,Yvonne Sherrer,Joel M. Kremer,C. Birbara,Jane Box,Kannan Natarajan,Isaac Nuamah,Tracy Li,Richard Aranda,David Hagerty,Maxime Dougados +13 more
TL;DR: Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy, including a clinically meaningful improvement in physical function.
Journal ArticleDOI
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Mark C. Genovese,James D. McKay,Evgeny Nasonov,Eduardo Mysler,Nilzio Antônio da Silva,Emma Alecock,Thasia G. Woodworth,Juan J. Gomez-Reino +7 more
TL;DR: Tocilizumab combined with any of the DMARDs evaluated was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents.
Journal ArticleDOI
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Mark C. Genovese,Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Grant W. Cannon,George Spencer-Green,Barbara K. Finck +13 more
TL;DR: Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.